Antibody Discovery Market Size, Share, Trends, Industry Analysis Report By Method (Phage Display, Hybridoma, Other), By Antibody Type, By End User, By Region – Market Forecast, 2025–2034
Description
The antibody discovery market size is expected to reach USD 20.41 billion by 2034, according to a new study by Polaris Market Research. The report “Antibody Discovery Market Size, Share, Trends, Industry Analysis Report By Method (Phage Display, Hybridoma, Other), By Antibody Type, By End User, By Region– Market Forecast, 2025–2034” gives a detailed insight into current market dynamics and provides analysis on future market growth.
Antibody discovery is the process of identifying and developing antibodies that can specifically bind to a target, such as a virus, bacterium, or cancer cell. It involves techniques such as hybridoma technology, phage display, or single B-cell screening to isolate and optimize effective antibodies. These antibodies are then characterized and tested for their potential use in diagnostics, therapeutics, or research.
Personalized medicine is transforming the way diseases are treated by focusing on therapies that are tailored to an individual’s genetic makeup and condition. Antibodies play a key role in this approach as they can be engineered to target specific molecules in the body, such as those found in cancer cells. The demand for customized antibody therapies is rising as more people and doctors prefer treatments that are more precise and have fewer side effects. This shift is especially important in fields such as oncology, where no two patients respond exactly the same way to treatment. Antibody discovery technologies enable the identification and development of highly specific treatments tailored to different patient groups. This trend is encouraging pharmaceutical companies to invest more in research that supports personalized approaches. As awareness and success stories around personalized medicine grow, it pushes the antibody discovery market forward, making it an essential part of future healthcare.
Strategic collaborations between biotech companies, pharmaceutical giants, academic institutions, and research labs are playing a big role in advancing antibody discovery. These partnerships allow different organizations to share resources, knowledge, and technology, making the discovery process faster and more effective. A research lab may have an advanced technological setup, while a pharmaceutical company may have the funding and manufacturing capabilities. Collaborations further help in managing the high cost and risk associated with drug development. Many companies now enter co-development or licensing agreements to share profits and responsibilities. This trend has led to a growing number of antibody-related drugs entering clinical trials and eventually reaching patients.
Antibody Discovery Market Report Highlights
In 2024, the phage display segment dominated with the largest share due to its versatility, reliability, and ability to produce high-affinity antibodies in a relatively short time.
The pharmaceutical and biotechnology industry segment is expected to experience significant growth during the forecast period as these companies are increasingly focused on developing biologic drugs, including monoclonal antibodies, to treat a wide range of conditions such as cancer, autoimmune diseases, and infectious diseases.
In 2024, North America dominated the antibody discovery market with the largest share due to its strong biomedical research infrastructure and consistent investments in life sciences.
The Asia Pacific antibody discovery market is experiencing significant growth driven by expanding biotech industries, supportive government initiatives, and increasing investments in healthcare research.
A few global key market players are Biocytogen, Charles River Laboratories, Creative Biolabs, Danaher Corporation, Eurofins Scientific, Evotec, Fairjourney Biologics S.A, Genscript Technology Corporation, Sartorius AG, and Twist Bioscience.
Polaris Market Research has segmented the antibody discovery market report on the basis of method, antibody type, end user, and region:
By Method (Revenue – USD Billion, 2020–2034)
Phage Display
Hybridoma
Others
By Antibody Type (Revenue – USD Billion, 2020–2034)
Humanized Antibody
Human Antibody
Chimeric Antibody
Murine Antibody
By End User (Revenue – USD Billion, 2020–2034)
Pharmaceutical and Biotechnology industry
Research laboratory
Academic laboratory
By Regional Outlook (Revenue – USD Billion, 2020–2034)
North America
U.S.
Canada
Mexico
Europe
Germany
UK
France
Italy
Spain
Russia
Netherlands
Rest of Europe
Asia Pacific
China
India
Japan
South Korea
Indonesia
Malaysia
Australia
Rest of Asia Pacific
Latin America
Argentina
Brazil
Rest of Latin America
Middle East & Africa
UAE
Saudi Arabia
Israel
South Africa
Rest of Middle East & Africa
Antibody discovery is the process of identifying and developing antibodies that can specifically bind to a target, such as a virus, bacterium, or cancer cell. It involves techniques such as hybridoma technology, phage display, or single B-cell screening to isolate and optimize effective antibodies. These antibodies are then characterized and tested for their potential use in diagnostics, therapeutics, or research.
Personalized medicine is transforming the way diseases are treated by focusing on therapies that are tailored to an individual’s genetic makeup and condition. Antibodies play a key role in this approach as they can be engineered to target specific molecules in the body, such as those found in cancer cells. The demand for customized antibody therapies is rising as more people and doctors prefer treatments that are more precise and have fewer side effects. This shift is especially important in fields such as oncology, where no two patients respond exactly the same way to treatment. Antibody discovery technologies enable the identification and development of highly specific treatments tailored to different patient groups. This trend is encouraging pharmaceutical companies to invest more in research that supports personalized approaches. As awareness and success stories around personalized medicine grow, it pushes the antibody discovery market forward, making it an essential part of future healthcare.
Strategic collaborations between biotech companies, pharmaceutical giants, academic institutions, and research labs are playing a big role in advancing antibody discovery. These partnerships allow different organizations to share resources, knowledge, and technology, making the discovery process faster and more effective. A research lab may have an advanced technological setup, while a pharmaceutical company may have the funding and manufacturing capabilities. Collaborations further help in managing the high cost and risk associated with drug development. Many companies now enter co-development or licensing agreements to share profits and responsibilities. This trend has led to a growing number of antibody-related drugs entering clinical trials and eventually reaching patients.
Antibody Discovery Market Report Highlights
In 2024, the phage display segment dominated with the largest share due to its versatility, reliability, and ability to produce high-affinity antibodies in a relatively short time.
The pharmaceutical and biotechnology industry segment is expected to experience significant growth during the forecast period as these companies are increasingly focused on developing biologic drugs, including monoclonal antibodies, to treat a wide range of conditions such as cancer, autoimmune diseases, and infectious diseases.
In 2024, North America dominated the antibody discovery market with the largest share due to its strong biomedical research infrastructure and consistent investments in life sciences.
The Asia Pacific antibody discovery market is experiencing significant growth driven by expanding biotech industries, supportive government initiatives, and increasing investments in healthcare research.
A few global key market players are Biocytogen, Charles River Laboratories, Creative Biolabs, Danaher Corporation, Eurofins Scientific, Evotec, Fairjourney Biologics S.A, Genscript Technology Corporation, Sartorius AG, and Twist Bioscience.
Polaris Market Research has segmented the antibody discovery market report on the basis of method, antibody type, end user, and region:
By Method (Revenue – USD Billion, 2020–2034)
Phage Display
Hybridoma
Others
By Antibody Type (Revenue – USD Billion, 2020–2034)
Humanized Antibody
Human Antibody
Chimeric Antibody
Murine Antibody
By End User (Revenue – USD Billion, 2020–2034)
Pharmaceutical and Biotechnology industry
Research laboratory
Academic laboratory
By Regional Outlook (Revenue – USD Billion, 2020–2034)
North America
U.S.
Canada
Mexico
Europe
Germany
UK
France
Italy
Spain
Russia
Netherlands
Rest of Europe
Asia Pacific
China
India
Japan
South Korea
Indonesia
Malaysia
Australia
Rest of Asia Pacific
Latin America
Argentina
Brazil
Rest of Latin America
Middle East & Africa
UAE
Saudi Arabia
Israel
South Africa
Rest of Middle East & Africa
Table of Contents
129 Pages
Pricing
Currency Rates
Questions or Comments?
Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.
